Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion.

CONTEXT Because surgical and medical therapies of acromegaly all have specific limitations, radiotherapy has been used as an adjunctive strategy. Stereotactic radiosurgery has not yet been widely evaluated. OBJECTIVE The objective was to perform an analysis of long-term hormonal effects and tolerance of gamma knife radiosurgery. DESIGN Eighty-two patients were prospectively studied over a decade, with a mean follow-up of 49.5 months. SETTING All patients were treated at the Department of Functional Neurosurgery of Marseille, France. PATIENTS The patients included 82 with active acromegaly, of whom 63 had previous transsphenoidal surgery. INTERVENTION Intervention included radiosurgery using the Leksell Gamma Unit B model. MAIN OUTCOME MEASURES Remission was diagnosed when mean GH levels were less than 2 ng/ml and IGF-I was normal for age off somatostatin agonists (at least 3 months). RESULTS Seventeen percent of the patients were in remission without any treatment. Twenty-three percent previously uncontrolled on somatostatin agonists fulfilled the same criteria after gamma knife while maintained on medical treatment. Initial GH and IGF-I levels off somatostatin agonists were significantly higher in uncured than in remission group (P = 0.01 and 0.047, respectively). Withdrawal of somatostatin agonists at the time of radiosurgery had no incidence on the outcome. No significant difference was found in success rate whether patients had previously been treated or not. Long-term side effects included complete (n = 2) or partial (n = 12) hypopituitarism diagnosed 1-7 yr after gamma knife. CONCLUSIONS Gamma knife radiosurgery may represent a therapeutic approach in patients with moderate initial or residual GH hypersecretion.

[1]  E. Lim,et al.  Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society. , 2005, The Journal of clinical endocrinology and metabolism.

[2]  P. Jenkins,et al.  Predicting Therapeutic Response and Degree of Pituitary Tumour Shrinkage during Treatment of Acromegaly with Octreotide LAR , 2004, Hormone Research in Paediatrics.

[3]  M. Brada,et al.  Radiosurgery for pituitary adenomas , 2004, Clinical endocrinology.

[4]  E. Laws,et al.  Stereotactic Radiosurgery for Pituitary Adenomas: A Review of the Literature , 2004, Journal of Neuro-Oncology.

[5]  G. Gamble,et al.  Factors influencing mortality in acromegaly. , 2004, The Journal of clinical endocrinology and metabolism.

[6]  P. Freda How effective are current therapies for acromegaly? , 2003, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[7]  E. Motti,et al.  Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. , 2003, Journal of Clinical Endocrinology and Metabolism.

[8]  J. Neal,et al.  Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission. , 2003, The Journal of clinical endocrinology and metabolism.

[9]  Hirohiko Nakamura,et al.  Gamma Knife Radiosurgery for Growth Hormone-Secreting Pituitary Adenomas Invading the Cavernous Sinus , 2002, Stereotactic and Functional Neurosurgery.

[10]  J. A. Scarlett,et al.  Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist , 2001, The Lancet.

[11]  M. Mayberg,et al.  Gamma Knife Radiosurgery in the Management of Patients with Acromegaly: A Review , 2001, Pituitary.

[12]  P. Epaminonda,et al.  Efficacy of radiotherapy in normalizing serum IGF‐I, acid‐labile subunit (ALS) and IGFBP‐3 levels in acromegaly , 2001, Clinical endocrinology.

[13]  Bin Wang,et al.  Radiosurgery for growth hormone—producing pituitary adenomas , 2000 .

[14]  J. Bertherat,et al.  Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. , 2000, The Journal of clinical endocrinology and metabolism.

[15]  F. Roelfsema,et al.  Postoperative radiotherapy in acromegaly is effective in reducing GH concentration to safe levels , 2000, Clinical endocrinology.

[16]  M. S. Tewart,et al.  Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000 .

[17]  S. Scheib,et al.  Octreotide may act as a radioprotective agent in acromegaly. , 2000, The Journal of clinical endocrinology and metabolism.

[18]  K. Takakura,et al.  Gamma Knife Radiosurgery for Pituitary Adenomas , 1999, Stereotactic and Functional Neurosurgery.

[19]  R. Huh,et al.  Gamma Knife Radiosurgery for Functioning Pituitary Adenomas , 1999, Stereotactic and Functional Neurosurgery.

[20]  J. Ganz,et al.  A Six Year Experience with the Postoperative Radiosurgical Management of Pituitary Adenomas , 1999, Stereotactic and Functional Neurosurgery.

[21]  G. Noren,et al.  Role of Gamma Knife Radiosurgery in Acromegaly , 1999, Pituitary.

[22]  E. Laws,et al.  Radiosurgery for pituitary tumors and craniopharyngiomas. , 1999, Neurosurgery clinics of North America.

[23]  Masaaki Yamamoto,et al.  Gamma Knife radiosurgery: technology, applications, and future directions. , 1999, Neurosurgery clinics of North America.

[24]  B. Rhee,et al.  Four Years’ Experiences in the Treatment of Pituitary Adenomas with Gamma Knife Radiosurgery , 1998, Stereotactic and Functional Neurosurgery.

[25]  K. Lamborn,et al.  Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. , 1998, The Journal of clinical endocrinology and metabolism.

[26]  P. Black,et al.  Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. , 1998, The Journal of clinical endocrinology and metabolism.

[27]  G. Bravo,et al.  Pituitary Tumors and Gamma Knife Surgery - Clinical Experience with More Than Two Years of Follow-Up , 1998, Stereotactic and Functional Neurosurgery.

[28]  S. Scheib,et al.  Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. , 1998, Journal of neurosurgery.

[29]  H. Sandler,et al.  Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. , 1997, The Journal of clinical endocrinology and metabolism.

[30]  J. Wass Long-term effects of radiotherapy for acromegaly. , 1996, Metabolism: clinical and experimental.

[31]  W. Young,et al.  Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study. , 1995, The Journal of clinical endocrinology and metabolism.

[32]  J. Flickinger,et al.  Tolerance of cranial nerves of the cavernous sinus to radiosurgery. , 1993, International journal of radiation oncology, biology, physics.

[33]  P. Gorden,et al.  Radiation therapy of acromegaly. , 1992, Endocrinology and metabolism clinics of North America.

[34]  J. Wass Evidence for the effectiveness of radiotherapy in the treatment of acromegaly. , 1997, The Journal of endocrinology.

[35]  J. Ganz,et al.  The effects of Gamma Knife surgery of pituitary adenomas on tumor growth and endocrinopathies. , 1993, Stereotactic and functional neurosurgery.